Matches in SemOpenAlex for { <https://semopenalex.org/work/W4238619792> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4238619792 endingPage "3547" @default.
- W4238619792 startingPage "3547" @default.
- W4238619792 abstract "Abstract Abstract 3547 Poster Board III-484 During graft-versus-host disease (GVHD), donor T cells become activated and migrate to tissue sites. Previously, we demonstrated a crucial role for the immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) in GVHD regulation. Here, we show that upon arrival in the colon, activated donor T cells produced IFN-γ that upregulated IDO, causing T cell anergy and apoptosis. IDO induces GCN2 kinase, upregulating a T cell stress response implicated in IDO immunosuppression. Donor T cells did not require GCN2 kinase to respond to IDO, suggesting toxic IDO metabolites, and not tryptophan depletion, were responsible for suppression. When exogenous metabolites were administered, GVHD lethality was reduced. To determine if IDO could be induced pre-transplantation for enhanced GVHD suppression, we first determined whether antigen presenting cells (APCs) or epithelial cells were primarily responsible for IDO expression and subsequent GVHD suppression. Recipients with wild-type vs. IDO−/− APCs had increased survival, regardless of epithelial cell expression of IDO, suggesting that APCs were suitable targets for inducing IDO. Administration of an agonist to toll-like receptor (TLR)-7/8, a receptor expressed primarily on APCs, induced IDO and reduced injury in the colon, and ameliorated lethality. We conclude that IDO upregulation may have therapeutic potential for preventing GVHD in the clinic. Disclosures: Mellor: NewLink Genetics, Inc.: Consultancy, Intellectual property interests in the therapeutic use of IDO and IDO inhibitors and receive consulting income and research support from NewLink Genetics, Inc., Research Funding. Munn:NewLink Genetics, Inc: Consultancy, Intellectual property interests in the therapeutic use of IDO and IDO inhibitors and receive consulting income and research support from NewLink Genetics, Inc, Patents & Royalties, Research Funding." @default.
- W4238619792 created "2022-05-12" @default.
- W4238619792 creator A5015771825 @default.
- W4238619792 creator A5045561472 @default.
- W4238619792 creator A5053593196 @default.
- W4238619792 creator A5054796938 @default.
- W4238619792 creator A5058268746 @default.
- W4238619792 creator A5060258620 @default.
- W4238619792 date "2009-11-20" @default.
- W4238619792 modified "2023-10-01" @default.
- W4238619792 title "Inducing the Tryptophan Catabolic Pathway, Indoleamine 2,3-Dioxygenase (IDO), for Suppression of Graft-Versus-Host Disease (GVHD) Lethality." @default.
- W4238619792 doi "https://doi.org/10.1182/blood.v114.22.3547.3547" @default.
- W4238619792 hasPublicationYear "2009" @default.
- W4238619792 type Work @default.
- W4238619792 citedByCount "0" @default.
- W4238619792 crossrefType "journal-article" @default.
- W4238619792 hasAuthorship W4238619792A5015771825 @default.
- W4238619792 hasAuthorship W4238619792A5045561472 @default.
- W4238619792 hasAuthorship W4238619792A5053593196 @default.
- W4238619792 hasAuthorship W4238619792A5054796938 @default.
- W4238619792 hasAuthorship W4238619792A5058268746 @default.
- W4238619792 hasAuthorship W4238619792A5060258620 @default.
- W4238619792 hasConcept C104317684 @default.
- W4238619792 hasConcept C126322002 @default.
- W4238619792 hasConcept C127561419 @default.
- W4238619792 hasConcept C203014093 @default.
- W4238619792 hasConcept C2776706248 @default.
- W4238619792 hasConcept C2779972918 @default.
- W4238619792 hasConcept C2780252810 @default.
- W4238619792 hasConcept C2911091166 @default.
- W4238619792 hasConcept C502942594 @default.
- W4238619792 hasConcept C515207424 @default.
- W4238619792 hasConcept C54355233 @default.
- W4238619792 hasConcept C71924100 @default.
- W4238619792 hasConcept C83478079 @default.
- W4238619792 hasConcept C86803240 @default.
- W4238619792 hasConceptScore W4238619792C104317684 @default.
- W4238619792 hasConceptScore W4238619792C126322002 @default.
- W4238619792 hasConceptScore W4238619792C127561419 @default.
- W4238619792 hasConceptScore W4238619792C203014093 @default.
- W4238619792 hasConceptScore W4238619792C2776706248 @default.
- W4238619792 hasConceptScore W4238619792C2779972918 @default.
- W4238619792 hasConceptScore W4238619792C2780252810 @default.
- W4238619792 hasConceptScore W4238619792C2911091166 @default.
- W4238619792 hasConceptScore W4238619792C502942594 @default.
- W4238619792 hasConceptScore W4238619792C515207424 @default.
- W4238619792 hasConceptScore W4238619792C54355233 @default.
- W4238619792 hasConceptScore W4238619792C71924100 @default.
- W4238619792 hasConceptScore W4238619792C83478079 @default.
- W4238619792 hasConceptScore W4238619792C86803240 @default.
- W4238619792 hasIssue "22" @default.
- W4238619792 hasLocation W42386197921 @default.
- W4238619792 hasOpenAccess W4238619792 @default.
- W4238619792 hasPrimaryLocation W42386197921 @default.
- W4238619792 hasRelatedWork W10397210 @default.
- W4238619792 hasRelatedWork W1413525 @default.
- W4238619792 hasRelatedWork W156741 @default.
- W4238619792 hasRelatedWork W3947919 @default.
- W4238619792 hasRelatedWork W4041773 @default.
- W4238619792 hasRelatedWork W5000387 @default.
- W4238619792 hasRelatedWork W7190444 @default.
- W4238619792 hasRelatedWork W8183651 @default.
- W4238619792 hasRelatedWork W8700225 @default.
- W4238619792 hasRelatedWork W9135849 @default.
- W4238619792 hasVolume "114" @default.
- W4238619792 isParatext "false" @default.
- W4238619792 isRetracted "false" @default.
- W4238619792 workType "article" @default.